PM|AM Split Dosing with MoviPrep
Improving the quality of your colonoscopy prep
MoviPrep is the first and only polyethylene glycol (PEG)–based osmotic prep approved by the FDA for a PM|AM Split Dosing regimen, in which you take the first dose of your colonoscopy prep the day before the procedure and complete the prep on the day of the procedure.
Research shows that the split dosing regimen improves the overall effectiveness and tolerability of the colonoscopy prep.1 In fact, the American College of Gastroenterology (ACG) now recommends split dosing to improve the quality of bowel preparations and colonoscopy.2 Completing the second part of your prep on the day of your colonoscopy helps cleanse the colon of any waste matter that has accumulated overnight. This has been shown to leave you with a cleaner colon than evening-only colonoscopy preps.1
Depending on the time of your procedure, taking MoviPrep with a PM|AM Split Dosing regimen may require you to wake up early in the morning to complete your prep. While this may seem like an inconvenience, think of it as time well spent toward proactively managing your colon health. In fact, when informed of the importance of a quality colonoscopy prep, 85% of patients surveyed said they would be willing to wake up as early as 2 or 3 AM for the second dose.3
Important Safety Information about MOVIPREP
MOVIPREP® (PEG-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid for oral solution) is an osmotic laxative indicated for cleansing of the colon as a preparation for colonoscopy in adults 18 years of age or older. MOVIPREP is contraindicated in patients with gastrointestinal (GI) obstruction, bowel perforation, gastric retention, ileus, toxic colitis or toxic megacolon, and patients who have had a severe hypersensitivity reaction to any of its components. MOVIPREP should be used with caution in patients at risk of or with fluid and electrolyte abnormalities, hyponatremia, arrhythmias, seizures, in patients with impaired renal function or patients taking concomitant medications that affect renal function, patients with known or suspected inflammatory bowel disease, patients with suspected GI obstruction or perforation, patients at risk for aspiration, and patients with glucose-6-phosphate dehydrogenase deficiency. Most common adverse reactions for split dosing (incidence ≥5%) are malaise, nausea, abdominal pain, vomiting, and upper abdominal pain. The most common adverse reactions for evening only dosing (incidence ≥5%) are abdominal distension, anal discomfort, thirst, nausea, abdominal pain, sleep disorder, rigors, hunger, malaise, vomiting, and dizziness. MOVIPREP contains 233 mg of phenylalanine per treatment. Advise patients to hydrate adequately before, during, and after the use of MOVIPREP.
You are encouraged to report negative side effects to the FDA. Visit www.fda.gov/safety/medwatch/ or call 1-800-FDA-1088.
Complete Prescribing Information 
For Dummies is a registered trademark of Wiley Publishing, Inc.
References: 1. Khan MA, Wasiuddin N, Brown M. Patient acceptance, convenience, and efficacy of one-day versus two-day colonoscopy bowel preparation. Poster presented at: Digestive Disease Week; May 20, 2008; San Diego, CA. 2. Rex DK, Johnson DA, Anderson JC, Schoenfeld PS, Burke CA, Inadomi JM. American College of Gastroenterology guidelines for colorectal cancer screening 2008. Am J Gastroenterol. 2009;104:739-750. 3. Unger RZ, Amstutz SP, Seo da H, Huffman M, Rex DK. Willingness to undergo split-dose bowel preparation for colonoscopy and compliance with split-dose instructions. Dig Dis Sci. 2010;55:2030-2034.